The EVOLVE Study: A Prospective, Observational Study to Evaluate Patient-centered Outcomes Over 2 Years of Treatment With Tezepelumab in Real-life Clinical Practice in Greece
Latest Information Update: 13 Dec 2024
Price :
$35 *
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms EVOLVE
- Sponsors AstraZeneca
- 13 Dec 2024 New trial record